Invest and Sell Be Biopharma Stock

Be Biopharma stock price

Forge Price ¹

Price not yet available

Last Closed Trade ²

Close Date

xx/xx/xx

Last Closed Trade Price

$xx.xx

Last Funding Round (LFR)

Date

xx/xx/xx

Price per Share

$xx.xx

Access Stock Price

Be Biopharma funding rounds and valuation

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	01/15/2025	Series C	$92.62MM	$xx.xx	$154.23MM	Alta Partners, Arch Venture Partners, Atlas Venture, Bristol Myers Squibb, Longwood Fund, Nextech, Ra Capital Management, Takeda Ventures
Price per Share $xx.xx Shares Outstanding 31,939,358 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Alta Partners, Arch Venture Partners, Atlas Venture, Bristol Myers Squibb, Longwood Fund, Nextech, Ra Capital Management, Takeda Ventures
	04/14/2022	Series B	$118MM	$xx.xx	$280.11MM	Alta Partners, Arch Venture Partners, Atlas Venture, Bristol Myers Squibb, Longwood Fund, Ra Capital Management, Takeda Ventures
Price per Share $xx.xx Shares Outstanding 5,870,638 Liquidation Pref Order 2 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Alta Partners, Arch Venture Partners, Atlas Venture, Bristol Myers Squibb, Longwood Fund, Ra Capital Management, Takeda Ventures
	10/22/2020	Series A	$64.1MM	$xx.xx	$91.57MM	Alta Partners, Atlas Venture, Longwood Fund, Ra Capital Management, Takeda Ventures
Price per Share $xx.xx Shares Outstanding 4,787,865 Liquidation Pref Order 2 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 0.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Alta Partners, Atlas Venture, Longwood Fund, Ra Capital Management, Takeda Ventures

Access Stock Price

Company details

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

be.bio

Sector

Healthcare

Subsector

Biotech & Pharma

Founded

2020

Headquarters

Cambridge, MA, United States

Post-Money Valuation ³

$154.23MM

Total Funding

$274.72MM

LFR Price per Share

$xx.xx

Last Funding Share Class

Series C

Be Biopharma stock FAQs

To buy and sell Be Biopharma stock

Can you buy Be Biopharma stock?

As Be Biopharma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Be Biopharma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Be Biopharma stock?

To invest in a private company like Be Biopharma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Be Biopharma stock?

Yes, you may sell the Be Biopharma stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Be Biopharma stock?

If you hold private company shares of Be Biopharma – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Be Biopharma on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about Be Biopharma stock

Is Be Biopharma a public company?

No, Be Biopharma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Be Biopharma’s stock price?

Be Biopharma is a privately held company and therefore does not have a public stock price. However, you may access Be Biopharma private market stock price with Forge Data.

What is Be Biopharma’s stock ticker symbol?

Be Biopharma does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Leadership and board

Leadership

Brad Hartman

Chief People Officer

Rick Morgan

Chief Scientific Officer

Lea Hachigian

Co-Founder & VP of Strategy

Joanne Smith-Farrell

Chief Executive Officer

Krishnan Viswanadhan

President & Chief Operating Officer

Board

Steven Gillis

Arch Venture Partners

Other companies like Be Biopharma in the Biotech & Pharma sector

Sector: Healthcare

Subsector: Biotech & Pharma

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	Altos Labs	--	--	$xx.xx	Series C	$6.33B	$xx.xx	$1.5B
	BillionToOne	--	--	$xx.xx	Series D	$1.25B	$xx.xx	$130.47MM
	Caris Life Sciences	--	--	$xx.xx	--	--	--	--
	Colossal Biosciences	--	--	$xx.xx	Series C	$10.2B	$xx.xx	$200MM
	Cytonics	--	--	$xx.xx	--	--	--	--
	Egenesis	--	--	$xx.xx	Series D	$332.59MM	$xx.xx	$90.96MM
	Isomorphic Labs	--	--	$xx.xx	--	--	--	--
	Kailera Therapeutics	--	--	$xx.xx	Series A-2 NV	$580.71MM	$xx.xx	$7.09MM
	Loyal	--	--	$xx.xx	Series B-5	$428.44MM	$xx.xx	$17.49MM
	Precision Neuroscience	--	--	$xx.xx	Series C	$542.69MM	$xx.xx	$102MM

See All Companies

Forge is your trusted partner to buy and sell Be Biopharma stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

First time buying private market stock?

New to selling your private company stock?

Updated on: Mar 13, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Be Biopharma stock